Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18435809 | ANTIBODY MOLECULE-DRUG CONJUGATES AND USES THEREOF | February 2024 | March 2025 | Abandon | 14 | 0 | 1 | No | No |
| 18393420 | Antibody Purification | December 2023 | September 2025 | Allow | 21 | 1 | 1 | No | No |
| 18528535 | CLEC12AXCD3 BISPECIFIC ANTIBODIES AND METHODS FOR THE TREATMENT OF DISEASE | December 2023 | October 2025 | Allow | 23 | 1 | 1 | No | No |
| 18494355 | IL-2 VARIANTS WITH REDUCED BINDING TO IL-2 RECEPTOR ALPHA AND USES THEREOF | October 2023 | August 2024 | Allow | 9 | 0 | 0 | No | No |
| 18489216 | ANTI-AVB6 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | October 2023 | December 2024 | Allow | 14 | 1 | 0 | No | No |
| 18478846 | Antibody Molecules to C5AR1 and Uses Thereof | September 2023 | May 2025 | Allow | 19 | 1 | 1 | No | No |
| 18472920 | ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF | September 2023 | April 2025 | Allow | 18 | 1 | 1 | No | No |
| 18452173 | Antibody Molecules to C5AR1 and Uses Thereof | August 2023 | August 2024 | Allow | 12 | 0 | 1 | No | No |
| 17811492 | CHIMERIC KLEBICINS | July 2022 | January 2026 | Allow | 43 | 3 | 1 | No | No |
| 17806566 | IL2-BASED THERAPEUTICS AND METHODS OF USE THEREOF | June 2022 | September 2025 | Allow | 39 | 3 | 1 | Yes | No |
| 17770439 | METHODS AND COMPOSITIONS FOR TREATING IRRITABLE BOWEL SYNDROME AND FUNCTIONAL DYSPEPSIA | April 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17767952 | METHODS OF USING IL-33 PROTEIN IN TREATING CANCERS | April 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17702329 | UPAR ANTIBODIES AND FUSION PROTEINS WITH THE SAME | March 2022 | February 2025 | Allow | 35 | 1 | 1 | No | No |
| 17753320 | TANDEM CD19 CAR-BASED COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | February 2022 | November 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17651020 | RECOMBINANT HAGFISH PROTEINS AND FIBERS | February 2022 | October 2024 | Allow | 32 | 2 | 1 | No | No |
| 17556061 | ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF | December 2021 | September 2024 | Allow | 33 | 2 | 1 | No | No |
| 17553333 | CLINICAL METHODS FOR USE OF A PD-L1-BINDING MOLECULE COMPRISING A SHIGA TOXIN EFFECTOR | December 2021 | August 2024 | Allow | 32 | 2 | 1 | No | No |
| 17548135 | ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF | December 2021 | October 2024 | Allow | 34 | 2 | 1 | No | No |
| 17609129 | ADC FOR A TREATMENT CONCOMITANT WITH OR SUBSEQUENT TO DOCETAXEL | November 2021 | September 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17608886 | E-CADHERIN ACTIVATING ANTIBODIES AND USES THEREOF | November 2021 | July 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17517111 | SUPRAMOLECULAR MODIFICATION OF PROTEINS | November 2021 | October 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17601908 | BIOMARKER FOR RHEUMATOID ARTHRITIS TREATMENT | October 2021 | July 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17484995 | Methods of Treating Influenza A Virus Infections | September 2021 | October 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17472237 | MULTI-SPECIFIC IMMUNE TARGETING MOLECULES AND USES THEREOF | September 2021 | February 2025 | Abandon | 41 | 3 | 1 | No | No |
| 17469625 | METHODS OF TREATING AUTOIMMUNE AND ALLOIMMUNE DISORDERS | September 2021 | January 2025 | Abandon | 41 | 2 | 1 | No | No |
| 17434368 | TSG-6 ANTIBODIES AND USES THEREFOR | August 2021 | August 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17428714 | TREATMENT OF DISEASES WITH MULTIMERIC PEPTIDES | August 2021 | October 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17423043 | REGULATION OF A FOREIGN BODY RESPONSE | July 2021 | October 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17297167 | ANTI SUPEROXIDE DISMUTASE 1 (SOD1) ANTIBODIES AND USE THEREOF | May 2021 | April 2025 | Allow | 46 | 1 | 1 | No | No |
| 17292883 | TISSUE PLASMINOGEN ACTIVATOR ANTIBODIES AND METHOD OF USE THEREOF | May 2021 | April 2025 | Allow | 47 | 1 | 1 | No | No |
| 17290157 | METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS | April 2021 | March 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17290129 | MULTIVALENT REGULATORY T CELL MODULATORS | April 2021 | January 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17287862 | Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy | April 2021 | February 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17231307 | IMMUNOSTIMULATORY AGENTS IN COMBINATION WITH ANGIOGENESIS INHIBITORS | April 2021 | November 2024 | Abandon | 43 | 3 | 0 | No | Yes |
| 17275092 | ANTI-TREM-2 AGONIST ANTIBODIES | March 2021 | July 2024 | Allow | 40 | 1 | 0 | No | No |
| 17271481 | NOVEL NUCLEASE DOMAIN AND USE THEREOF | February 2021 | December 2024 | Allow | 46 | 2 | 1 | Yes | No |
| 17173767 | CHROMATOGRAPHY RESIN AND USES THEREOF | February 2021 | October 2024 | Allow | 44 | 3 | 1 | No | No |
| 17267331 | Anti-Follicle Stimulating Hormone Receptor Antibodies | February 2021 | December 2025 | Allow | 58 | 3 | 1 | No | No |
| 17266993 | COMPOSITIONS AND METHODS RELATED TO OVERCOMING INNATE IMMUNE BARRIERS TO CANCER IMMUNOTHERAPY | February 2021 | April 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17266024 | ANTI-CD137 ANTIGEN-BINDING MOLECULE AND UTILIZATION THEREOF | February 2021 | January 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17265876 | MULTI-SPECIFIC BINDING PROTEINS THAT BIND HER2, NKG2D, AND CD16, AND METHODS OF USE | February 2021 | December 2024 | Allow | 46 | 1 | 1 | Yes | No |
| 17264545 | OPTIMIZED SYNTHETIC CONSENSUS IMMUNOGENIC COMPOSITIONS TARGETING CHONDROITIN SULFATE PROTEOGLYCAN 4 (CSPG4) | January 2021 | August 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17259714 | FC BINDING FRAGMENTS COMPRISING AN OX40 ANTIGEN-BINDING SITE | January 2021 | January 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17125456 | GENOME EDITING IN BACTEROIDES | December 2020 | April 2025 | Abandon | 52 | 4 | 1 | No | No |
| 16949278 | Cladribine regimen for treating progressive forms of Multiple Sclerosis | October 2020 | April 2024 | Allow | 41 | 1 | 0 | No | No |
| 17041835 | CAR-TREG-BASED THERAPIES FOR TREATING NEURODEGENERATIVE DISEASES | September 2020 | September 2024 | Allow | 48 | 1 | 1 | No | No |
| 17040016 | BIOMARKER COMBINATION FOR IDENTIFICATION OF "AT-RISK" SUBJECTS FOR AKI | September 2020 | April 2025 | Abandon | 55 | 2 | 1 | No | No |
| 16980742 | ENGINEERED CELLS, T CELL IMMUNE MODULATING ANTIBODIES AND METHODS FOR USING THE SAME | September 2020 | November 2024 | Allow | 50 | 1 | 1 | No | No |
| 16980354 | ANTI- POLYSIALIC ACID ANTIBODIES AND USES THEREOF | September 2020 | September 2024 | Allow | 48 | 1 | 1 | No | No |
| 16948219 | COMBINATION THERAPY FOR THE TREATMENT OF MIGRAINES | September 2020 | March 2025 | Allow | 54 | 3 | 1 | Yes | Yes |
| 17002860 | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses | August 2020 | March 2025 | Abandon | 55 | 3 | 0 | No | No |
| 16945709 | METHOD FOR TREATING SEIZURES | July 2020 | January 2025 | Abandon | 54 | 3 | 1 | No | No |
| 16929411 | COMPOSITIONS FOR AND METHODS OF DIAGNOSING, PROGNOSING, AND TREATING DIABETES | July 2020 | July 2024 | Allow | 48 | 2 | 1 | Yes | No |
| 16958960 | Anti-Renalase Antibodies for the Treatment and Prevention of Diseases and Disorders | June 2020 | September 2024 | Allow | 51 | 1 | 1 | Yes | No |
| 16614691 | COMPOSITIONS AND METHODS FOR CELL TARGETING THERAPIES | November 2019 | August 2024 | Allow | 56 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DONOGHUE, BRITTNEY ERIN.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DONOGHUE, BRITTNEY ERIN works in Art Unit 1675 and has examined 40 patent applications in our dataset. With an allowance rate of 52.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.
Examiner DONOGHUE, BRITTNEY ERIN's allowance rate of 52.5% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DONOGHUE, BRITTNEY ERIN receive 1.60 office actions before reaching final disposition. This places the examiner in the 30% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by DONOGHUE, BRITTNEY ERIN is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +61.3% benefit to allowance rate for applications examined by DONOGHUE, BRITTNEY ERIN. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 36.4% of applications are subsequently allowed. This success rate is in the 82% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 22.2% of cases where such amendments are filed. This entry rate is in the 28% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.5% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.